HeartSciences Inc.
HSCSNext catalyst
Empagliflozin
Obesity
Get an email about HSCS's next catalysts
Track HeartSciences (HSCS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
HSCS Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.74 | FQ end Oct/2026 | Call: tbd
Empagliflozin Phase 2 Est. Readout (CRAVE)
Estimated primary completion for Empagliflozin trial (NCT06570473) in Pulmonary Hypertension. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
tissue plasminogen activator
Myocardial Infarction
Beta adrenergic blockers
Cardiovascular Diseases
Sildenafil Citrate
Pulmonary Fibrosis
Betamethasone
Pregnancy
Standard medical therapy
Heart Failure
Secondary Prophylaxis
Rheumatic Heart Disease
Eszopiclone
Sleep Apnea
Tadalafil
Fontan Palliation
Surfactant
Infant, Newborn, Diseases
amiodarone
Atrial Fibrillation
LY3819253
Covid19
Esomeprazole
Asthma
Tacrolimus
Leukemia, Myelocytic, Acute
daily fluticasone propionate
Asthma
Furosemide-Q12 hour bolus
Heart Failure
Vitamin D ergocalciferol
Renal Function
Sulfonylurea (glimepiride)
Type 2 Diabetes
Standard antimicrobial therapy
Neutropenia
Low dose methotrexate
Vascular Inflammation
niacin
Cardiovascular Diseases
Short storage RBC age
Anemia
UFH or LMWH
Venous Thromboembolism
Hydrocortisone
Infant, Newborn
Omega-3 fatty acids (fish oil)
Cardiovascular Disease
Recombinant tissue plasminogen activator (rt-PA)
Deep Vein Thrombosis
Pitavastatin
HIV
Entresto Pill
Congenital Heart Disease
treosulfan
Accelerated Phase Chronic Myelogenous Leukemia
Ranolazine
Pulmonary Hypertension
H1N1 vaccine high dose
H1N1 Influenza Virus
Recombinant human erythropoietin alfa (drug)
Myocardial Infarction
Oxygen
Obstructive Sleep Apnea
Atomoxetine and Oxybutynin (ato-oxy)
Obstructive Sleep Apnea
Aspirin
Acute Respiratory Distress Syndrome
liothyronine
Heart Failure With Preserved Ejection Fraction
Adult stem cells
Left Ventricular Dysfunction
Sodium Nitrite
Pulmonary Hypertension Secondary
Hematopoietic Stem Cell Transplant
Hemophagocytic Lymphohistiocytosis
Carbasalate calcium
Cerebral Hemorrhage
Perhexiline
Chronic Heart Failure
2-Hydroxybenzylamine
Atrial Fibrillation
Sodium Nitroprusside (SNP)
Stress Disorders, Post-Traumatic
vitamin C
Cardiovascular Diseases
Glycine Buffer
Cystic Fibrosis
Amino Acid infusion
Acute Kidney Injury
MPC Intramyocardial Injection
Heart Failure
Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training
Peripheral Arterial Disease
TRIA-662
Hypertriglyceridemia
Levofloxacin
Sarcoidosis; Antimycobacterial Therapy
BIO-11006 Inhalation Solution
COPD
Magnesium Sulfate, Heptahydrate
Asthma
Atomoxetine
Sleep Apnea
Dapagliflozin
Chronic Kidney Diseases
Empagliflozin
Obesity
Chelation therapy
Anemia (Iron-Loading)
Anakinra
Heart Failure With Normal Ejection Fraction
Lentiviral G1XCGD Gene Therapy
Granulomatous Disease, Chronic, X-linked
Epi-743
Methylmalonic Aciduria and Homocystinuria,Cblc Type
sugar pill
Heart Failure
Alendronic Acid
Calcific Aortic Stenosis
AMD3100
Fanconi Anemia
To Measure levels of circulating monocyte/T cell doublets at Baseline
Post-Acute COVID-19 Syndrome
Maraviroc
Primary Graft Dysfunction
Sacubitril, Valsartan
Diabetes Mellitus
clopidogrel
Hypertension, Pulmonary
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
tissue plasminogen activator | Phase 3 | Myocardial Infarction | - | - |
Beta adrenergic blockers | Phase 3 | Cardiovascular Diseases | - | - |
Sildenafil Citrate | Phase 3 | Pulmonary Fibrosis | - | - |
Betamethasone | Phase 3 | Pregnancy | - | - |
Standard medical therapy | Phase 3 | Heart Failure | - | - |
Secondary Prophylaxis | Phase 3 | Rheumatic Heart Disease | - | - |
Eszopiclone | Phase 3 | Sleep Apnea | - | - |
Tadalafil | Phase 3 | Fontan Palliation | - | - |
Surfactant | Phase 3 | Infant, Newborn, Diseases | - | - |
amiodarone | Phase 3 | Atrial Fibrillation | - | - |
LY3819253 | Phase 3 | Covid19 | - | - |
Esomeprazole | Phase 3 | Asthma | - | - |
Tacrolimus | Phase 3 | Leukemia, Myelocytic, Acute | - | - |
daily fluticasone propionate | Phase 3 | Asthma | - | - |
Furosemide-Q12 hour bolus | Phase 3 | Heart Failure | - | - |
Vitamin D ergocalciferol | Phase 3 | Renal Function | - | - |
Sulfonylurea (glimepiride) | Phase 3 | Type 2 Diabetes | - | - |
Standard antimicrobial therapy | Phase 3 | Neutropenia | - | - |
Low dose methotrexate | Phase 3 | Vascular Inflammation | - | - |
niacin | Phase 3 | Cardiovascular Diseases | - | - |
Short storage RBC age | Phase 3 | Anemia | - | - |
UFH or LMWH | Phase 3 | Venous Thromboembolism | - | - |
Hydrocortisone | Phase 3 | Infant, Newborn | - | - |
Omega-3 fatty acids (fish oil) | Phase 3 | Cardiovascular Disease | - | - |
Recombinant tissue plasminogen activator (rt-PA) | Phase 3 | Deep Vein Thrombosis | - | - |
Pitavastatin | Phase 3 | HIV | - | - |
Entresto Pill | Phase 3 | Congenital Heart Disease | - | - |
treosulfan | Phase 2 | Accelerated Phase Chronic Myelogenous Leukemia | - | - |
Ranolazine | Phase 2 | Pulmonary Hypertension | - | - |
H1N1 vaccine high dose | Phase 2 | H1N1 Influenza Virus | - | - |
Recombinant human erythropoietin alfa (drug) | Phase 2 | Myocardial Infarction | - | - |
Oxygen | Phase 2 | Obstructive Sleep Apnea | - | - |
Atomoxetine and Oxybutynin (ato-oxy) | Phase 2 | Obstructive Sleep Apnea | - | - |
Aspirin | Phase 2 | Acute Respiratory Distress Syndrome | - | - |
liothyronine | Phase 2 | Heart Failure With Preserved Ejection Fraction | - | - |
Adult stem cells | Phase 2 | Left Ventricular Dysfunction | - | - |
Sodium Nitrite | Phase 2 | Pulmonary Hypertension Secondary | - | - |
Hematopoietic Stem Cell Transplant | Phase 2 | Hemophagocytic Lymphohistiocytosis | - | - |
Carbasalate calcium | Phase 2 | Cerebral Hemorrhage | - | - |
Perhexiline | Phase 2 | Chronic Heart Failure | - | - |
2-Hydroxybenzylamine | Phase 2 | Atrial Fibrillation | - | - |
Sodium Nitroprusside (SNP) | Phase 2 | Stress Disorders, Post-Traumatic | - | - |
vitamin C | Phase 2 | Cardiovascular Diseases | - | - |
Glycine Buffer | Phase 2 | Cystic Fibrosis | - | - |
Amino Acid infusion | Phase 2 | Acute Kidney Injury | - | - |
MPC Intramyocardial Injection | Phase 2 | Heart Failure | - | - |
Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training | Phase 2 | Peripheral Arterial Disease | - | - |
TRIA-662 | Phase 2 | Hypertriglyceridemia | - | - |
Levofloxacin | Phase 2 | Sarcoidosis; Antimycobacterial Therapy | - | - |
BIO-11006 Inhalation Solution | Phase 2 | COPD | - | - |
Magnesium Sulfate, Heptahydrate | Phase 2 | Asthma | - | - |
Atomoxetine | Phase 2 | Sleep Apnea | - | - |
Dapagliflozin | Phase 2 | Chronic Kidney Diseases | - | - |
Empagliflozin | Phase 2 | Obesity | - | - |
Chelation therapy | Phase 2 | Anemia (Iron-Loading) | - | - |
Anakinra | Phase 2 | Heart Failure With Normal Ejection Fraction | - | - |
Lentiviral G1XCGD Gene Therapy | Phase 2 | Granulomatous Disease, Chronic, X-linked | - | - |
Epi-743 | Phase 2 | Methylmalonic Aciduria and Homocystinuria,Cblc Type | - | - |
sugar pill | Phase 2 | Heart Failure | - | - |
Alendronic Acid | Phase 2 | Calcific Aortic Stenosis | - | - |
AMD3100 | Phase 2 | Fanconi Anemia | - | - |
To Measure levels of circulating monocyte/T cell doublets at Baseline | Phase 2 | Post-Acute COVID-19 Syndrome | - | - |
Maraviroc | Phase 2 | Primary Graft Dysfunction | - | |
Sacubitril, Valsartan | Phase 2 | Diabetes Mellitus | - | - |
clopidogrel | Phase 2 | Hypertension, Pulmonary | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in HeartSciences Inc.'s drug pipeline?→
CatalystAlert tracks 65 drug candidates in HeartSciences Inc.'s (HSCS) pipeline across Phase 3, Phase 2. Its lead program is amiodarone (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is HeartSciences Inc.'s next FDA catalyst?→
HeartSciences Inc.'s (HSCS) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HSCS biotech catalysts?→
Add HSCS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow HeartSciences Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.